{
  "source": "PA-Notification-Javygtor.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1057-14\nProgram Prior Authorization/Notification\nMedication Javygtor™ (sapropterin dihydrochloride)*, Kuvan® (sapropterin\ndihydrochloride)*\nP&T Approval Date 4/2008, 4/2009, 3/2010, 3/2011, 1/2012, 2/2013, 10/2013, 10/2014,\n10/2015, 9/2016, 9/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022,\n3/2023, 3/2024, 3/2025\nEffective Date 6/1/2025\n1. Background:\nJavygtor and Kuvan are phenylalanine hydroxylase activators indicated to reduce blood\nphenylalanine (Phe) levels in adult and pediatric patients one month of age and older with\nhyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria\n(PKU). Javygtor and Kuvan are to be used in conjunction with a Phe-restricted diet.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Javygtor* and Kuvan* will be approved based on all of the following criteria:\na. Diagnosis of phenylketonuria (PKU)\n-AND-\nb. Patient is actively on a Phe-restricted diet\n-AND-\nc. Patient is not receiving the requested medication in combination with Palynziq\n(pegvaliase-pqpz)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Javygtor* and Kuvan* will be approved based on all of the following criteria:\na. Patient is actively on a Phe-restricted diet\n-AND-\nb. Blood Phe levels continue to remain lower than baseline level\n-AND-\n© 2025 UnitedHealthcare Services Inc.\n1\nc. Patient is not receiving the requested medication in combination with Palynziq\n(pegvaliase-pqpz)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Javygtor and Brand Kuvan are typically excluded from coverage. Tried/Failed criteria may be in\nplace. Please refer to plan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, Unit",
    "lly excluded from coverage. Tried/Failed criteria may be in\nplace. Please refer to plan specifics to determine exclusion status.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may also be in place.\n4. References:\n1. Kuvan [package insert]. Novato, CA: BioMarin Pharmaceutical Inc.; August 2024.\n2. Javygtor [package insert]. Princeton, NJ: Dr. Reddy’s Laboratories, Inc.; October 2024.\n3. Javygtor powder for oral solution [package insert]. Princeton, NJ: Dr. Reddy’s Laboratories,\nInc.; October 2024.\n4. Smith WE, Berry SA, Bloom K, et al. Phenylalanine hydroxylase deficiency diagnosis and\nmanagement: A 2023 evidence-based clinical guideline of the American College of Medical\nGenetics and Genomics (ACMG). Genet Med. 2025;27(1):101289.\ndoi:10.1016/j.gim.2024.101289\nProgram Prior Authorization/Notification – Javygtor and Kuvan (sapropterin\ndihydrochloride)\nChange Control\n10/2013 Removed age criterion.\n10/2014 Annual review. Updated references.\n10/2015 Annual review. Updated authorization period to 6 mo. Updated\nreauthorization requirement. Background edit. Updated references.\n9/2016 Annual review. Updated references.\n9/2017 Annual review with no changes to coverage criteria.\n7/2018 Added criteria restricting combination use with Palynziq\n12/2018 Administrative change to add statement regarding use of automated\nprocesses.\n7/2019 Annual review with no changes to coverage criteria. Updated reference.\n7/2020 Annual review with no changes to coverage criteria. Updated reference.\n7/2021 Annual review with no changes to clinical criteria. Updated re-\nauthorization to 12 months. Added statement that Brand Kuvan is\nexcluded from coverage for the majority of our benefits. Updated\nbackground and refere",
    "with no changes to clinical criteria. Updated re-\nauthorization to 12 months. Added statement that Brand Kuvan is\nexcluded from coverage for the majority of our benefits. Updated\nbackground and references.\n© 2025 UnitedHealthcare Services Inc.\n2\n7/2022 Annual review with no changes to coverage criteria. Added state\nmandate footnote.\n3/2023 Added Javygtor to program. Updated exclusion footnote and\nreferences.\n3/2024 Annual review. Updated authorization approval duration to 12 months.\nUpdated reference.\n3/2025 Annual review. Updated references.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}